AnaptysBio (NasdaqGS:ANAB) FY Conference Transcript

AnaptysBio FY Conference Summary Company Overview - AnaptysBio is a biotechnology company with over 20 years of experience in developing antibodies, currently preparing to spin off its biopharma operations into a new entity called First Tracks Biotherapeutics [6][4] - The company has two successful programs: - Jemperli (dostarlimab), an oncology drug sold by GSK, which generated approximately $1.4 billion in revenue last year, translating to about $100 million in royalties for AnaptysBio [19][111] - Imsidolimab, which is expected to have a Phase 2 readout by the end of the year and is anticipated to be sold by Vanda [6][6] Financial Structure Post-Separation - AnaptysBio will retain a royalty-based financial structure with high EBIT margins in the mid-high 90% range, minimal operational expenses (less than $10 million annually), and fewer than 10 full-time employees [17][25] - The company expects to be cash flow positive by mid-2027, with a projected need for $100 million to fund the biopharma business into Q3 of 2027 and $200 million to fully fund it into the latter half of 2028 [32][34] Pipeline and Product Development ANB033 (CD122 Antagonist) - ANB033 is being developed for Celiac Disease and Eosinophilic Esophagitis (EoE), with a Phase 1b trial design that includes two cohorts: one undergoing a gluten challenge and another with patients showing signs of mucosal injury [38][50] - The trial aims to measure histological outcomes and symptom severity, with results expected in Q4 of this year [68][66] - The company believes it has a competitive edge due to its dual-targeting mechanism, which blocks both IL-2 and IL-15 pathways [70][78] EoE Program - The EoE trial is set to initiate with a 50-patient cohort, focusing on histological outcomes and patient-reported outcomes (PRO) [84][85] - The approach targets TH2 CD4 cells and ILC2s, differentiating it from Dupixent, the only approved therapeutic for EoE, which targets eosinophils directly [90][91] Competitive Landscape - AnaptysBio faces competition from other companies targeting the IL-15/CD122 pathway, including Teva and Novartis, but believes its dual-targeting approach provides a distinct advantage [71][75] - The company is optimistic about its potential to address a broader patient population, including those who are Dupixent-experienced and Dupixent-naive [95][96] Royalty Business and Future Outlook - The royalty business is anchored by Jemperli, which is projected to grow significantly, with GSK aiming for peak sales of $2.7 billion by 2029, resulting in close to $400 million in royalties for AnaptysBio [111][113] - The company is focused on protecting and maximizing the value from existing royalties rather than expanding into new drugs [111][112] - AnaptysBio anticipates exiting the year with two commercial-stage royalties, including imsidolimab, which is awaiting approval for generalized pustular psoriasis [122][122] Conclusion - AnaptysBio is strategically positioning itself for growth through the separation of its biopharma operations, a strong pipeline of innovative therapies, and a robust royalty business model that leverages existing successful products [6][4][111]